Advertisement

Topics

Brilinta (TM) - ticagrelor, AstraZeneca's new heart drug - Biotech, Pharma and Life Science Channel

20:31 EST 18th November 2018 | BioPortfolio

Brilinta

Brilinta - ticagrelor, AstraZeneca's new heart drug is a blood-thinning medicine designed to prevent dangerous blood clots in patients with serious chest pain or previous heart attacks. It reduces the clumping of blood particles, called platelets, that promote clotting.

Analysts believe that peak sales of Brilinta could reach $2bn or more, but Brilinta will face stiff competition in the blood-thinning market, notably from Plavix.

What is BRILINTA?

BRILINTA is a type of prescription antiplatelet medication for people who have had a recent heart attack or severe chest pain that happened because their heart wasn't getting enough oxygen and who are being treated with medicines or procedures to open blocked arteries in the heart. BRILINTA is used with aspirin to stop platelets from sticking together and forming a blood clot that could block blood flow to the heart and cause another, possibly fatal, heart attack. Platelets are small cells in the blood that help with normal blood clotting.

Why BRILINTA?

BRILINTA used with aspirin lowers your chance of having another serious problem with your heart or blood vessels such as heart attack, stroke, or blood clots in your stent if you received one. These can be fatal. In fact, in a large clinical study BRILINTA was even better than Plavix® (clopidogrel bisulfate) tablets at lowering your chances of having another heart attack.

Key documents: Patient Prescribing Information ~ Medication Guide

BRILINTA is a trademark of the AstraZeneca group of companies.

Plavix® is a registered trademark of sanofi-aventis.

News Articles [7 Associated News Articles listed on BioPortfolio]

SMS Pharmaceuticals Ltd SMSPHARMA Financial and Strategic SWOT Analysis Review [Report Updated: 26092018] Prices from USD $125

SMS Pharmaceuticals Ltd SMSPHARMA Financial and Strategic SWOT Analysis Review provides you an indepth strategic SWOT analysis of the company's businesses and operations. The profile has been compile...

SMS Pharmaceuticals Ltd SMSPHARMA Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 24092018] Prices from USD $250

SummarySMS Pharmaceuticals Ltd SMS Pharma is a manufacturer of active pharmaceutical ingredients APIs and intermediates that develops offers antifungal, antiulcer, antimigraine, antihypersensitive, an...

The Landmark DECLARE-TIMI 58 Cardiovascular Outcomes Trial of FARXIGA in Patients with Type 2 Diabetes to Be Featured at AHA 2018

New data on cardiovascular effects of long-term BRILINTA use in patients with a history of heart attack Data from 20 abstracts further highlight AstraZeneca’s holistic ...

Global Peripheral Arterial Disease PAD Drugs Market Status and Outlook 20182025 [Report Updated: 01082018] Prices from USD $4000

Report SnapshotKey Content of Chapters Including and can be customized, report is a semifinished version, and it takes 4872 hours to upgradePart 1:Terminology Definition, Industry Chain,Industry Dynam...

PhaseBio Announces Positive Results From Phase 1 Clinical Trial of PB2452, a Novel Reversal Agent for Ticagrelor

MALVERN, Pa. and SAN DIEGO, Calif., Sept. 24, 2018 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the development and commercialization of...

Human medicines European public assessment report (EPAR): Brilique, ticagrelor, Revision: 11, Authorised

SMS Pharmaceuticals Ltd SMSPHARMA Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 25042018] Prices from USD $250

SummarySMS Pharmaceuticals Ltd SMS Pharma is a manufacturer of active pharmaceutical ingredients APIs and intermediates that develops offers antifungal, antiulcer, antimigraine, antihypersensitive, an...

Events [0 Results]

None

Companies [0 Results]

None

Clinical Trials [155 Associated Clinical Trials listed on BioPortfolio]

Personalization of Long-Term Antiplatelet Therapy

In patients after myocardial infarction (MI) (heart attacks) and treated with percutaneous coronary intervention (PCI), the current standard is dual antiplatelet therapy (DAPT), with aspir...

Chewed Versus Integral Pill of Ticagrelor

Hypothesis The primary question the investigators propose to answer is whether all patients undergoing PCI with stent deployment who receive chewed ticagrelor will demonstrate more rapid d...

Low-dose of Ticagrelor and Standard-dose Clopidogrel on Platelet Effects in Chinese Patients With Stable CAD.

Ticagrelor has been demonstrated to provide a more rapid and more powerful inhibition of platelet aggregation compared with clopidogrel in coronary artery disease (CAD) patients. However, ...

Recurrent Events After Percutaneous Coronary INterventio for ACS

Patients undergoing PCI for ACS are exposed to a significant ischemic and bleeding risk. The aim of our study is instead to analyze in detail the rates of recurrent events, but also their...

Registry of Acute Coronary Syndrome From University Hospital of Vigo

CardoCHUVI registry was aim to study ischemic and bleeding complication after an acute coronary syndrome (ACS), both in-hospital and follow-up events.

Effect of Free Ticagrelor Fraction on Platelet Membrane Post MI

The purpose of this study is to assess: - the population pharmacokinetics of unbound ticagrelor and its metabolite in acute coronary syndrome patients treated by ticagrelor ...

Chronic Kidney Disease (CKD) Platelet Study

This study evaluates how aspirin, clopidogrel and ticagrelor work in people with chronic kidney disease (CKD) compared to people with normal kidneys. In the first part of the study, half o...

Efficacy and Safety of Low Dose Ticagrelor in Patients With Unstable Angina Pectoris After Coronary Stent Implantation

The study is to evaluate efficacy and safety of low dose of ticagrelor therapy for Chinese patients treated with non-urgent coronary stent implantation, to examine whether lower dose ticag...

Ticagrelor and Clopidogrel on Platelet Aggregation in Clopidogrel Resistance's Patients With CHD

The study sought to observe the effects of optimal dose of ticagrelor(90 mg qd)ticagrelor and double standard-dose clopidogrel on platelet reactivity in coronary heart disease patients ...

Effect of Diabetes and Hepatic Enzymes Mutation on Clopidogrel VS Ticagrelor Actity in MI Patients Undergoing Primary PCI

In this study the combined effect of diabetes mellitus and cyp2c19 polymorphism on platelet aggregation inhibitory activity of the highest traditionally used loading dose 600 mg clopidogre...

PubMed Articles [35 Associated PubMed Articles listed on BioPortfolio]

Pharmacokinetic-pharmacodynamic modelling of platelet response to ticagrelor in stable coronary artery disease and prior myocardial infarction patients.

To characterize ticagrelor exposure-response relationship for platelet inhibition in patients with stable coronary artery disease (CAD) and a history of myocardial infarction (MI), using non-linear mi...

Accurate measurement of endogenous adenosine in human blood.

Accurate determination of in vivo circulating concentrations of extracellular adenosine in blood samples is challenging due to the rapid formation and rapid clearance of adenosine in blood. A blood co...

MANAGEMENT IF ANTIPLATELET THERAPY FOR NON-ELECTIVE INVASIVE PROCEDURES OF BLEEDING COMPLICATIONS: PROPOSALS FROM THE FRENCH WORKING GROUP ON PERIOPERATIVE HAEMOSTATSIS (GIHP) AND THE FRENCH STUDY GROUP ON THROMBOSIS AND HAEMOSTASIS (GFHT), IN COLLABORATION WITH THE FRENCH SOCIETY OF ANAESTHESIA AND INTENSIVE CARE MEDICINE (SFAR).

The French Working Group on Perioperative Haemostasis (GIHP) and the French Study Group on Haemostasis and Thrombosis (GFHT) in collaboration with the French Society for Anaesthesia and Intensive Care...

Choosing between ticagrelor and clopidogrel following percutaneous coronary intervention: A systematic review and Meta-Analysis (2007-2017).

Limitations have been observed with the use of clopidogrel following percutaneous coronary intervention (PCI) indicating the urgent need of a more potent anti-platelet agent. We aimed to compare the e...

Are all P2Y12 equally effective in vein graft angioplasty? A report from the UK database.

Information of P2Y12 inhibitors in acute coronary syndromes with vein graft angioplasty is limited. This new analysis from the UK database was not able to find significant differences between Clopidog...

Meta-Analysis of Potent P2Y12-ADP Receptor Antagonist Therapy Compared to Clopidogrel Therapy in Acute Coronary Syndrome Patients with Chronic Kidney Disease.

 The clinical benefit of anti-platelet agents in patients with chronic kidney disease (CKD) is uncertain. In addition, the risk-benefit ratio of potent oral P2Y12-adenosine diphosphate (ADP) recepto...

Reorganization of platelet membrane sphingomyelins by adenosine diphosphate and ticagrelor.

Platelets are major targets for the treatment of thrombo-embolic disorders. Their plasma membrane contains specialized microdomains enriched in sphingomyelins and free cholesterol including membrane r...

Pretreatment with ticagrelor may offset additional inhibition of platelet and coagulation activation with bivalirudin compared to heparin during primary percutaneous coronary intervention.

It remains unknown if bivalirudin compared to heparin confers any additional inhibition of platelet and coagulation activation during primary percutaneous coronary intervention (PPCI) after pretreatme...

The impact of in-hospital P2Y12 inhibitor switch in patients with acute coronary syndrome.

Dual antiplatelet therapy (DAPT) varies after placement of drug-eluting stents (DES) in patients presenting with acute coronary syndromes (ACS). Our aim was to study patient characteristics and predic...

Size matters in STEMI: time for translation of ticagrelor?

Videos

None available.

Medical and Biotech [MESH] Definitions

None available.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Cardiology
Cardiology is a specialty of internal medicine.  Cardiac electrophysiology : Study of the electrical properties and conduction diseases of the heart. Echocardiography : The use of ultrasound to study the mechanical function/physics of the h...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

review and buy Brilinta (TM) - ticagrelor, AstraZeneca's new heart drug market research data and corporate reports here

Channels Quicklinks